Key Insights on Sanofi Stock – What Investors Need to Know

Large-cap Health Care company Sanofi has moved 3.7% so far today on a volume of 5,106,431, compared to its average of 2,321,582. In contrast, the S&P 500 index moved -0.0%.

Sanofi trades -17.17% away from its average analyst target price of $59.12 per share. The 5 analysts following the stock have set target prices ranging from $55.0 to $65.0, and on average have given Sanofi a rating of buy.

Anyone interested in buying SNY should be aware of the facts below:

  • Sanofi's current price is -35.1% below its Graham number of $75.42, which implies the stock has a margin of safety

  • Sanofi has moved -11.7% over the last year, and the S&P 500 logged a change of 26.2%

  • Based on its trailing earnings per share of 1.94, Sanofi has a trailing 12 month Price to Earnings (P/E) ratio of 25.2 while the S&P 500 average is 27.65

  • SNY has a forward P/E ratio of 10.1 based on its forward 12 month price to earnings (EPS) of $4.87 per share

  • The company has a price to earnings growth (PEG) ratio of 1.27 — a number near or below 1 signifying that Sanofi is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 0.83 compared to its sector average of 3.61

  • Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

  • Based in Paris, the company has 86,088 full time employees and a market cap of $122.87 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.